Results 61 to 70 of about 30,099 (284)

RNA interference approaches for treatment of HIV-1 infection. [PDF]

, 2015
HIV/AIDS is a chronic and debilitating disease that cannot be cured with current antiretroviral drugs. While combinatorial antiretroviral therapy (cART) can potently suppress HIV-1 replication and delay the onset of AIDS, viral mutagenesis often leads to
Bobbin, Maggie L, Burnett, John C, Rossi, John J   +2 more
core   +1 more source

Affinity Proteomics‐Based Non‐Invasive Detection of Clinically Significant Liver Disease

Alimentary Pharmacology &Therapeutics, EarlyView.
Using UK Biobank proteomic data, we identified a five‐protein score reflecting hepatic stellate cell activation and hepatocellular injury that predicts major adverse liver outcomes and clinically significant fibrosis, with consistent performance validated in two independent cohorts (patients with HIV and alpha1‐antitrypsin deficiency).
Sriram Balasubramani, Katharina Remih, Anna Sophie Karl, Julia Alexandra Borchert, Christina Schrader, Malin Fromme, Can Kayatekin, Bailin Zhang, Mikhail Levit, Pavithra Krishnaswami, Louise E. van Eekeren, Leo A. B. Joosten, Twan Otten, Petra Tomanová, Pavel Strnad   +14 more
wiley   +1 more source

Considerations for the Use of AAV‐based Gene Therapy in HIV‐Positive Individuals With Haemophilia

Haemophilia, EarlyView.
ABSTRACT Introduction There is a high prevalence of human immunodeficiency virus (HIV) infection among the haemophilia community due to treatment in the 1970s and 1980s with contaminated clotting factor. Lifelong treatment regimens for haemophilia and HIV are burdensome alone and pose a particular challenge for individuals living with both conditions ...
Jürgen K. Rockstroh, Julia C. Stingl, Marco Stadler, Anja Reichert, Heiner Wedemeyer, Johannes Oldenburg   +5 more
wiley   +1 more source

Viral Dynamic Model of Antiretroviral Therapy Including the Integrase Inhibitor Raltegravir in Patients with HIV-1

Biomath, 2012
Antiviral combination therapies consisting of reverse transcriptase inhibitors, protease inhibitors and an integrase inhibitor, have been developed to suppress HIV below the limit of detection.
Dimitra Bon, Christoph Stephan, Oliver Keppler, Eva Herrmann   +3 more
doaj   +1 more source

The Hepatitis B Virus Ribonuclease H Is Sensitive to Inhibitors of the Human Immunodeficiency Virus Ribonuclease H and Integrase Enzymes [PDF]

, 2013
Nucleos(t)ide analog therapy blocks DNA synthesis by the hepatitis B virus (HBV) reverse transcriptase and can control the infection, but treatment is life-long and has high costs and unpredictable long-term side effects.
A Agrawal, A Monto, Aleem Siddiqui, AM Woltman, B Werle-Lapostolle, C Chang, CA Shaw-Reid, CS Coffin, CW Shepard, D Ganem, D Lavanchy, DK Wong, DM Himmel, DM Himmel, E Michailidis, E. Jon Jacobsen, Eleftherios Michailidis, ER Goedken, F Cao, F Dyda, F Kurbanov, F van Bommel, F Zoulim, F Zoulim, F Zoulim, Feng Cao, G Radziwill, G Radziwill, G Woo, GJ Klarmann, GK Lau, GM Di, GR Foster, H Fuji, H Kwon, H Pelletier, H Wang, HP Su, HR Bokesch, J Beck, J Cheng, J Choi, J Didierjean, J Hu, J Hu, J Wu, J zu Putlitz, JE Tavis, JE Tavis, JJ Arnold, JJ Song, JL Keck, John E. Tavis, JS Tuttleman, JT Edward, K Katayanagi, K Klumpp, K Klumpp, K Takada, K Wursthorn, L Lin, LJ Chang, M Ariyoshi, M Billamboz, M Billamboz, M Buti, M Chen, M Ghany, M Levrero, M Nowotny, M Nowotny, M Ruggeri, M Sturmer, M Wendeler, M Wu, Marvin J. Meyers, MD Li, Michael A. Parniak, Michael Totten, ML Op den Brouw, MT Chen, N Cox, N Potenza, O Poch, P Frank, P Frank, P Marcellin, P Vanlandschoot, PA Rice, PD Williams, PN Cheng, Q Gong, Rajeev Aurora, RP Perrillo, S Chung, S Chung, SR Budihas, Stefan G. Sarafianos, T Gerelsaikhan, TA Kirschberg, V Suchaud, W Yang, WF Lima, WF Lima, X Wei, Xiaohong Cheng, Y Chen, Y Gong, Y Wei, Y Xu, YF Liaw, YI Lee, Yuan Hu   +112 more
core   +3 more sources

Exploring the impact of Cabotegravir‐Rilpivirine long‐acting on weight gain, body composition and quality of life in adults living with HIV

HIV Medicine, EarlyView.
Abstract Introduction Long‐acting injectable antiretroviral therapy (ART) with Cabotegravir (CAB) and Rilpivirine (RPV) offers an alternative to daily oral regimens, improving adherence and patient satisfaction. However, its impact on body composition and metabolism remains underexplored.
Andrea De Vito, Andrea Marongiu, Antonella Cano, Mariangela Puci, Agnese Colpani, Susanna Maria Nuvoli, Maria Grazia Catte, Giulia Moi, Maria Antonietta Deledda, Sergio Uzzau, Giovanni Sotgiu, Franca Deriu, Angela Spanu, Giordano Madeddu   +13 more
wiley   +1 more source

Efficacy of Integrase Strand Transfer Inhibitors and the Capsid Inhibitor Lenacapavir against HIV-2, and Exploring the Effect of Raltegravir on the Activity of SARS-CoV-2

Viruses
Retroviruses perpetuate their survival by incorporating a copy of their genome into the host cell, a critical step catalyzed by the virally encoded integrase.
Irene Wanjiru Kiarie, Gyula Hoffka, Manon Laporte, Pieter Leyssen, Johan Neyts, József Tőzsér, Mohamed Mahdi   +6 more
doaj   +1 more source

HIV-1 acquired drug resistance to integrase inhibitors in a cohort of antiretroviral therapy multi-experienced Mexican patients failing to raltegravir: a cross-sectional study

AIDS Research and Therapy, 2020
Background In resource-limited settings, multi-experienced HIV infected patients are often prescribed raltegravir for salvage therapy. Patients failing raltegravir-containing regimens require other drugs including other integrase inhibitors.
Aurelio Orta-Resendiz, Roberto A. Rodriguez-Diaz, Luis A. Angulo-Medina, Mario Hernandez-Flores, Luis E. Soto-Ramirez   +4 more
doaj   +1 more source

Transcription activator like effector (TALE)-directed piggyBac transposition in human cells. [PDF]

, 2013
Insertional therapies have shown great potential for combating genetic disease and safer methods would undoubtedly broaden the variety of possible illness that can be treated. A major challenge that remains is reducing the risk of insertional mutagenesis
Bhakta, Mital S, Kim, Moon-Soo, Mauro, Damiano, Moisyadi, Stefan, Owens, Jesse B, Segal, David J, Stoytchev, Ilko   +6 more
core   +3 more sources

Virological outcomes with Bictegravir/Emtricitabine/Tenofovir alafenamide (B/F/TAF) in people previously treated with darunavir‐based antiretroviral therapy

HIV Medicine, EarlyView.
Abstract Background Darunavir‐based antiretroviral therapy (ART) is commonly used in people with HIV who experience adherence challenges and/or have complex resistance patterns. Changes in ART commissioning have led to an increased use of Bictegravir/Emtricitabine/Tenofovir alafenamide (B/F/TAF) in these populations despite limited real‐world outcome ...
Rhianna Sheridan, Yasmin Osei‐Kuffour Ekert, Lucy Campbell, Mark Zuckerman, Sally Hawkins, Kate Childs, Frank A. Post   +6 more
wiley   +1 more source